End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36.95 CNY | -4.40% | -4.27% | +27.46% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.25 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.46% | 2.61B | D+ | ||
+18.64% | 71.4B | C+ | ||
-6.00% | 23.08B | C+ | ||
+3.18% | 8.55B | C | ||
+9.32% | 8.43B | B | ||
-25.47% | 7.46B | B- | ||
+13.25% | 5.23B | B- | ||
+1.58% | 4.29B | B- | ||
+5.71% | 3.89B | B+ | ||
+0.76% | 4.03B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000028 Stock
- Ratings China National Accord Medicines Corporation Ltd.